Lung Cancer Therapy

Global Lung Cancer Therapy Market to Reach US$77.5 Billion by 2030

The global market for Lung Cancer Therapy estimated at US$38.2 Billion in the year 2024, is expected to reach US$77.5 Billion by 2030, growing at a CAGR of 12.5% over the analysis period 2024-2030. Noninvasive Therapy, one of the segments analyzed in the report, is expected to record a 14.2% CAGR and reach US$51.2 Billion by the end of the analysis period. Growth in the Minimally Invasive Therapy segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.4 Billion While China is Forecast to Grow at 17.1% CAGR

The Lung Cancer Therapy market in the U.S. is estimated at US$10.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$16.5 Billion by the year 2030 trailing a CAGR of 17.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 11.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.9% CAGR.

Global Lung Cancer Therapy Market – Key Trends & Drivers Summarized

Why Is Lung Cancer Therapy Undergoing a Major Transformation in the Modern Medical Landscape?

Lung cancer therapy has entered a period of rapid transformation, driven by advancements in medical science, early detection strategies, and a deeper understanding of cancer biology. As one of the most prevalent and deadly forms of cancer worldwide, lung cancer has long presented challenges due to its late-stage diagnosis and aggressive nature. Historically dominated by surgery, chemotherapy, and radiation, treatment approaches are now evolving to include targeted therapies, immunotherapies, and personalized medicine. Non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancer cases, is now being treated based on specific genetic mutations and biomarkers such as EGFR, ALK, and ROS1, allowing for more precise and effective interventions. Meanwhile, small cell lung cancer (SCLC), known for its rapid progression, is also seeing improvements in therapeutic options through the use of combination regimens and novel agents. Multidisciplinary care involving oncologists, pulmonologists, radiologists, and pathologists is becoming the standard, facilitating better decision-making and individualized care plans. Advances in imaging technologies, liquid biopsies, and molecular profiling are enabling earlier and more accurate diagnoses, increasing the potential for successful outcomes. Patient advocacy and global awareness campaigns are also driving earlier screenings and greater access to treatment, especially in high-risk populations such as smokers and individuals with occupational exposure. With continuous investment in research and a pipeline full of innovative therapies, lung cancer treatment is moving toward a more hopeful future where outcomes are steadily improving and long-term remission becomes an increasingly realistic goal.

How Are Targeted Therapies and Immunotherapies Revolutionizing the Treatment of Lung Cancer?

The rise of targeted therapies and immunotherapies is revolutionizing lung cancer treatment by offering tailored approaches that address the molecular drivers of the disease rather than relying on broadly toxic systemic treatments. Targeted therapies work by inhibiting specific genetic mutations that fuel cancer growth, such as EGFR mutations or ALK rearrangements in NSCLC patients. These therapies, including tyrosine kinase inhibitors (TKIs), have demonstrated superior efficacy and fewer side effects compared to traditional chemotherapy. Additionally, advancements in next-generation sequencing allow for the identification of rare mutations, expanding treatment eligibility and improving precision in therapy selection. Immunotherapies, particularly immune checkpoint inhibitors like PD-1 and PD-L1 inhibitors, are reshaping the landscape by enabling the body’s immune system to recognize and destroy cancer cells. These agents have significantly extended survival rates in patients with advanced disease and are increasingly being used in combination with chemotherapy or as maintenance therapy following initial response. The introduction of combination immunotherapy regimens is yielding impressive clinical results, particularly in tumors with high mutational burdens or immune responsiveness. Research is also focusing on overcoming resistance to targeted therapies and enhancing immune responses through novel agents such as cancer vaccines, adoptive T-cell therapy, and bispecific antibodies. The integration of these innovative approaches is not only prolonging survival but also improving the quality of life for many lung cancer patients. As regulatory agencies expedite approvals for promising treatments, and as real-world data continues to support their use, the role of targeted and immune-based therapies in lung cancer care will only continue to grow.

What Emerging Trends in Diagnostics and Patient Management Are Influencing Lung Cancer Therapy?

The evolution of diagnostics and patient management strategies is playing a pivotal role in shaping the future of lung cancer therapy, enhancing early detection, treatment personalization, and overall patient outcomes. One of the most impactful trends is the increased use of low-dose computed tomography (LDCT) screening in high-risk populations, which has proven effective in identifying lung cancer at earlier, more treatable stages. Molecular diagnostics are now routine in clinical settings, with tests that profile tumors for actionable mutations using tissue or blood samples, a practice known as liquid biopsy. These non-invasive tests are enabling ongoing monitoring of disease progression and treatment response, allowing for timely adjustments to therapy. Artificial intelligence and machine learning algorithms are being integrated into imaging and pathology workflows to improve diagnostic accuracy and reduce time to treatment. Patient-centric care models are also emerging, emphasizing shared decision-making, psychological support, and multidisciplinary coordination. Telemedicine and digital health tools are expanding access to care, particularly in remote or underserved areas, while also supporting continuous monitoring of patient symptoms and treatment adherence. Clinical decision support systems are assisting healthcare providers in selecting optimal therapies based on individual patient profiles and the latest evidence-based guidelines. Enhanced focus on survivorship and long-term care is addressing issues such as fatigue, lung function, and secondary malignancies, ensuring that quality of life remains a central aspect of therapy planning. Together, these innovations in diagnostics and care management are supporting a more proactive, precise, and patient-centered approach to lung cancer treatment.

What Are the Main Drivers Behind the Global Growth of the Lung Cancer Therapy Market?

The growth in the global lung cancer therapy market is driven by a convergence of factors related to technological innovation, increasing disease burden, improved healthcare infrastructure, and rising demand for personalized care. A key driver is the rising incidence of lung cancer worldwide, fueled by aging populations, continued tobacco use in certain regions, environmental pollution, and occupational hazards. This growing patient base is prompting both public and private sectors to invest heavily in oncology research, diagnostics, and treatment facilities. Another major factor is the accelerating development and commercialization of novel therapies, including targeted drugs and immunotherapies, which offer improved outcomes and are rapidly being adopted across clinical settings. Regulatory bodies are streamlining approval processes for breakthrough treatments, often providing fast-track designations and orphan drug status to expedite market entry. Advancements in biomarker research and genomics are enabling the design of highly specific therapies that improve efficacy and reduce adverse effects, aligning with global trends in precision medicine. In addition, expanding access to healthcare services in emerging economies is increasing treatment uptake, supported by government funding and international health initiatives. Pharmaceutical collaborations and mergers are strengthening research pipelines and broadening treatment portfolios. Furthermore, growing awareness among patients about screening and treatment options is enhancing early diagnosis rates and treatment initiation. As clinical guidelines evolve to incorporate cutting-edge therapies and as healthcare providers embrace integrated care models, the lung cancer therapy market is poised for sustained and substantial growth across both developed and developing regions.

SCOPE OF STUDY:

The report analyzes the Lung Cancer Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Therapy (Noninvasive Therapy, Minimally Invasive Therapy); Indication (Non-Small Cell Lung Cancer, Small Cell Lung Cancer); End-Use (Hospitals End-Use, Oncology Clinics End-Use, Research Centers End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• AbbVie, Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• Gilead Sciences / Kite Pharma
• GlaxoSmithKline plc (GSK)
• Hoffmann-La Roche Ltd (Roche)
• Johnson & Johnson (Janssen Pharmaceuticals)
• Merck & Co., Inc.
• Moderna Therapeutics
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Seagen Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more